These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32115329)

  • 1. Is the clinical benefit of implantable cardioverter-defibrillators in heart failure patients declining?
    Spartalis M; Iliopoulos DC; Spartalis E; Athanasiou A; Paschou SA; Voudris V; Siasos G
    J Cardiol; 2020 May; 75(5):583-584. PubMed ID: 32115329
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.
    Wolff G; Lin Y; Karathanos A; Brockmeyer M; Wolters S; Nowak B; Fürnkranz A; Makimoto H; Kelm M; Schulze V
    Clin Res Cardiol; 2017 Jul; 106(7):501-513. PubMed ID: 28213711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure.
    Rami T; Shih HT
    Curr Opin Cardiol; 2004 May; 19(3):264-9. PubMed ID: 15096960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH).
    Oseroff O; Retyk E; Bochoeyer A
    Curr Opin Cardiol; 2004 Jan; 19(1):26-30. PubMed ID: 14688631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure and Implantable Cardioverter Defibrillator (ICD) therapy: Update and perspective on current primary prevention trials.
    Saxon LA
    J Card Fail; 2002 Jun; 8(3):161-6. PubMed ID: 12140809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of implantable cardioverter-defibrillator therapy in heart failure.
    Can I; Tholakanahalli VN
    Curr Heart Fail Rep; 2009 Sep; 6(3):199-209. PubMed ID: 19723462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
    Böcker D; Breithardt G
    Am J Cardiol; 1999 Mar; 83(5B):83D-87D. PubMed ID: 10089846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important Parameters for Implantable Cardioverter Defibrillator Selection.
    Zungsontiporn N; Loguidice M; Daniels J
    Card Electrophysiol Clin; 2018 Mar; 10(1):145-152. PubMed ID: 29428136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure patients unresponsive to implantable cardioverter-defibrillator therapy: a neglected problem.
    Disertori M; Masè M; Rigoni M; Nollo G; Ravelli F
    Eur J Heart Fail; 2019 Dec; 21(12):1507-1509. PubMed ID: 31332922
    [No Abstract]   [Full Text] [Related]  

  • 14. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The "clinical cost" of implantable cardioverter-defibrillators in the primary prevention of sudden cardiac death should not restrict their use].
    Francia P; Cappato R
    G Ital Cardiol (Rome); 2011 May; 12(5):379-82; discussion 382. PubMed ID: 21593958
    [No Abstract]   [Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Leyva F; Israel CW; Singh J
    Circulation; 2023 Feb; 147(9):759-767. PubMed ID: 36848410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indication of implantable cardioverter defibrillator for heart failure].
    Noda T; Kamakura S
    Nihon Rinsho; 2007 May; 65 Suppl 5():195-9. PubMed ID: 17571384
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking?
    Uretsky BF; Sheahan RG
    J Am Coll Cardiol; 1997 Dec; 30(7):1589-97. PubMed ID: 9385881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
    Schrage B; Uijl A; Benson L; Westermann D; Ståhlberg M; Stolfo D; Dahlström U; Linde C; Braunschweig F; Savarese G
    Circulation; 2019 Nov; 140(19):1530-1539. PubMed ID: 31476893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.